Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epstein-Barr virus envelope glycoprotein GP350 (gp350) is the most abundant glycoprotein on the outer envelope of the Epstein-Barr virus (EBV) virion and is also expressed on the surface of EBV-infected cells during the lytic cycle. It plays a critical role in initiating viral infection by binding to complement receptor 2 (CR2/CD21) on host B lymphocytes, facilitating viral attachment and subsequent membrane fusion and entry. Because of its prominent surface exposure and essential role in viral entry, gp350 is a primary target for prophylactic and therapeutic interventions against EBV-associated diseases, including infectious mononucleosis, multiple sclerosis, and various malignancies such as Burkitt lymphoma, nasopharyngeal carcinoma, and post-transplant lymphoproliferative disorders (PTLD).
Therapeutic strategies targeting gp350 include subunit and nanoparticle vaccines (e.g., gp350-ferritin nanoparticle vaccine, gp350/AS04 vaccine) and multi-antigen mRNA vaccines (e.g., mRNA-1189, mRNA-1195) designed to elicit neutralizing antibodies that block viral attachment. Additionally, monoclonal antibodies (such as S54 and 72A1) and chimeric antigen receptor T-cell (CAR-T) therapies are being developed to neutralize the virus and selectively eliminate gp350-expressing cells in patients with chronic active EBV or EBV-positive malignancies.
Active immunization to induce neutralizing antibodies, passive immunization to block receptor binding, and CAR-T cell-mediated cytotoxicity against gp350-expressing cells.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epstein-Barr virus envelope glycoprotein GP350 (gp350).